SYRE Stock Summary and Trading Ideas (Spyre Therapeutics | NASDAQ:SYRE)

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.

Spyre Therapeutics trades on the NASDAQ stock market under the symbol SYRE.

As of January 3, 2025, SYRE stock price climbed to $24.35 with 203,799 million shares trading.

SYRE has a beta of 1.84, meaning it tends to be more sensitive to market movements. SYRE has a correlation of 0.08 to the broad based SPY ETF.

SYRE has a market cap of $1.43 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that SYRE belongs to (by Net Assets): VTI, IWM, VXF, XBI, IBB.

SYRE has underperformed the market in the last year with a return of +16.0%, while the SPY ETF gained +27.8%. In the last 3 month period, SYRE fell short of the market, returning -14.2%, while SPY returned +4.6%. However, in the most recent 2 weeks SYRE has outperformed the stock market by returning +2.1%, while SPY returned +0.1%.

SYRE support price is $22.66 and resistance is $25.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SYRE shares will trade within this expected range on the day.